NEWS 86 FEED & ADDITIVE MAGAZINE November 2024 USA-based company ADM reached an agreement to acquire Vandamme Hungaria Kft and its related entities, which operate a 700 metric ton/day non-GM crush and extraction facility in Northern Hungary. "The enduring global trends of food security and sustainability are driving demand for non-GM products, with 60% of consumers in a European survey saying that non-GM is a claim they like to see on product packaging, and ADM is investing to ensure we can meet this growing demand," says Sebastian Kuck, ADM's General Manager of EU Soybean Crush. "After a multiyear process of extending our non-GM soybean offerings from our crush facilities in Becej, Serbia as well as Straubing and Mainz, Germany, we are thrilled to add this state-of-the-art soy and corn germ switch plant to further enable us to meet the needs of our non-GM customers in the food, feed, pet and oil markets." The Komárom, Hungary-based production facility was built in 2010, and transforms soybeans and corn germ into meal and oils for customers in Europe and the Middle East. It has 38 colleagues, and reportedly delivered revenues of approximately €114 million in 2023. "Our growing footprint in the European non-GM soybean segment also supports our farmer suppliers by offering an outlet for a much-needed value-added crop which can help with crop rotation and provide a platform from which to enhance their regenerative agricultural practices," explains Rene van der Poel, ADM Commercial Manager. "We're proud to partner with farmers across Europe, and believe these investments represent yet another way in which we're adding to our capabilities and demonstrating our unique ability to meet varied customer needs, including when EU deforestation regulations come into law." Read more>> Researchers at Nofima, in collaboration with other European research institutions in Ireland and Spain, made new discoveries in the exploration of deep-sea fish. The study was recently published in a renowned scientific journal. The results show that deep-sea mesopelagic fish species such as hatchetfish and lanternfish could be a source of new medicines and health-promoting ingredients. These underutilised fish species may contain unique substances that could be beneficial for human health. This study generated bioactive hydrolysates (which are proteins split into peptides) using an enzyme and natural autolysis from deep-sea fish. The scientists then investigated if the hydrolysates could have biological effects by using “in vitro bioassays” to reveal potential bioactivity, and thereafter identified the bioactive peptides by using advanced “mass spectrometry” methods. The study has identified special protein fragments in deep-sea fish which may have anti-inflammatory properties. These small peptides could potentially be used to create new medicines for pain and chronic inflammatory conditions. The substances also have the potential to positively influence blood pressure and blood sugar levels. Read more>> ADM adds non-GM capabilities in Hungary with new agreement New study suggests deep-sea fish offer health benefits
RkJQdWJsaXNoZXIy MTUxNjkxNQ==